Depósito Digital de Documentos de la UAB Encontrados 7 registros  La búsqueda tardó 0.01 segundos. 
1.
3 p, 1.0 MB Unmasking the expression of PD-L1 in Myeloid Derived Suppressor Cells : A case study in lung cancer to discover new drugs with specific on-target efficacy / G. Rico, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Aguilar Hernández, A. (Quirón Dexeus University Hospital. Dr Rosell Oncology Institute) ; Ward, M.D. (Thermo Fisher Scientific) ; Bradford, J.A. (Thermo Fisher Scientific) ; Junca, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Petriz, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
2021 - 10.1016/j.tranon.2020.100969
Translational Oncology, Vol. 14 Núm. 1 (january 2021) , p. 100969  
2.
11 p, 515.9 KB Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain / Rodríguez-Lescure, A. (Hospital General Universitario de Elche. Medical Oncology Department) ; de la Peña, F. A. (Hospital Universitario Morales Meseguer. Haematology and Medical Oncology Department) ; Aranda, E. (Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, University of Córdoba, Spanish Cancer Network (RTICC), Instituto de Salud Carlos III. Oncology Department) ; Calvo, A. (Hospital General Universitario Gregorio Marañón) ; Felip, E. (Hospital Universitari Vall d'Hebron) ; Garrido, P. (Hospital Universitario Ramón Y Cajal. Medical Oncology Department) ; Vera, R. (Complejo Hospitalario de Navarra, Navarrabiomed, IdISNA. Medical Oncology Department) ; Universitat Autònoma de Barcelona
The Spanish Society of Medical Oncology (SEOM) has carried out a study to analyse the conditions of access to oncology drugs in clinical practice in Spain. For the first time, the access of predictive biomarkers has also been analyzed. [...]
2020 - 10.1007/s12094-020-02366-y
Clinical & Translational Oncology, Vol. 22 (june 2020) , p. 2253-2263  
3.
16 p, 1003.6 KB Update of the recommendations for the determination of biomarkers in colorectal carcinoma : National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology / García-Alfonso, P. (Hospital General Universitario Gregorio Marañón) ; García-Carbonero, R. (Departament of Medical Oncology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), UCM, CNIO, CIBERONC, Madrid, Spain) ; García-Foncillas, J. (Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma de Madrid. Departament of Medical Oncology) ; Pérez-Segura, P. (Hospital Clínico Universitario San Carlos, CIBERONC. Departament of Medical Oncology) ; Salazar, R. (Departament of Medical Oncology, ICO L'Hospitalet, Oncobell Program (IDIBELL), CIBERONC, Hospitalet de Llobregat, Spain) ; Vera, R. (Complejo Hospitalario de Navarra; Navarrabiomed, IDISNA. Departament of Medical Oncology) ; Ramón y Cajal, S. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Hernández-Losa, J. (Hospital Universitari Vall d'Hebron) ; Landolfi, S. (VHIO) ; Musulén, E. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Cuatrecasas, M. (Hospital Clinic, CIBERehd. Department of Pathology) ; Navarro, S. (Hospital Clínic Universitari (València)) ; Universitat Autònoma de Barcelona
In this update of the consensus of the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica-SEOM) and the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica-SEAP), advances in the analysis of biomarkers in advanced colorectal cancer (CRC) as well as susceptibility markers of hereditary CRC and molecular biomarkers of localized CRC are reviewed. [...]
2020 - 10.1007/s12094-020-02357-z
Clinical & Translational Oncology, Vol. 22 (may 2020) , p. 1976-1991  
4.
8 p, 1.4 MB Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma / Trilla-Fuertes, Lucía (Biomedica Molecular Medicine SL, C/Faraday 7, 28049, Madrid, Spain) ; Ghanem, Ismael (Medical Oncology Department, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain) ; Maurel, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; G-Pastrián, Laura (Molecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain) ; Mendiola, Marta (Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Av. Monforte de Lemos 5, 28029, Madrid, Spain) ; Peña, Cristina (Pathology Department, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain) ; López-Vacas, Rocío (Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain) ; Prado-Vázquez, Guillermo (Biomedica Molecular Medicine SL, C/Faraday 7, 28049, Madrid, Spain) ; López-Camacho, Elena (Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain) ; Zapater-Moros, Andrea (Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain) ; Heredia, Victoria (Translational Oncology Lab, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain) ; Cuatrecasas, Miriam (Pathology Department, Hospital Clínic Universitari de Barcelona, Carrer de Villarroel 170, 08036, Barcelona, Spain) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Capdevila, Jaume (Vall d'Hebron Institut d'Oncologia) ; Conill, Carles (Radiotherapy Oncology Department, Hospital Clínic Universitari de Barcelona, Carrer de Villarroel 170, 08036, Barcelona, Spain) ; García-Carbonero, Rocío (Medical Oncology Department, Hospital Universitario 12 de Ocubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), UCM, CNIO, CIBERONC, Av. Córdoba s/n, 28041, Madrid, Spain) ; Heath, Karen E. (Institute of Medical and Molecular Genetics, IdiPAZ, Hospital Universitario La Paz /& CIBERER, Unit 753, ISCIII, Paseo de la Castellana 261, 28046, Madrid, Spain) ; Ramos-Ruiz, Ricardo (Genomics Unit Cantoblanco, Parque Científico de Madrid, C/ Faraday 7, 28049, Madrid, Spain) ; Llorens, Carlos (Biotechvana SL, Parque Científico de Madrid, C/ Faraday 7, 28049, Madrid, Spain) ; Campos-Barros, Ángel (Institute of Medical and Molecular Genetics, IdiPAZ, Hospital Universitario La Paz /& CIBERER, Unit 753, ISCIII, Paseo de la Castellana 261, 28046, Madrid, Spain) ; Gámez-Pozo, Angelo (Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain) ; Feliu, Jaime (Cátedra UAM-Amgen, Universidad Autónoma de Madrid, Ciudad Universitaria de Cantoblanco, 28049, Madrid, Spain) ; Vara, Juan Ángel Fresno (Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain)
Anal squamous cell carcinoma (ASCC) is a rare neoplasm. Chemoradiotherapy is the standard of care, with no therapeutic advances achieved over the past three decades. Thus, a deeper molecular characterization of this disease is still necessary. [...]
2020 - 10.1016/j.tranon.2020.100778
Translational Oncology, Vol. 13 (may 2020)  
5.
15 p, 955.9 KB SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018) / Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Juan, O. (Hospital Universitari i Politècnic La Fe de Valencia) ; Insa, A. (Hospital Clínico Universitario de Valencia) ; Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ; Trigo, J. M. (Hospital Universitario Virgen de la Victoria) ; Carcereny, E. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; García-Campelo, R. (Complexo Hospitalario Universitario A Coruña) ; García, Y. (Universitat Autònoma de Barcelona. Departament de Medicina) ; Guirado, M. (Hospital General Universitario de Elche. Medical Oncology Department) ; Provencio, M. (Universidad Autónoma de Madrid.Hospital Universitario Puerta de Hierro) ; Universitat Autònoma de Barcelona
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular knowledge; so, more options can be offered to patients with driver mutations. [...]
2018 - 10.1007/s12094-018-1978-1
Clinical & Translational Oncology, Vol. 21 (november 2018) , p. 3-17  
6.
10 p, 402.2 KB SEOM clinical guideline for treatment of kidney cancer (2017) / Gallardo, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Méndez-Vidal, M. J. (Instituto Maimónides de Investigación Biomédica de Córdoba) ; Pérez-Gracia, J. L. (Clínica Universidad de Navarra) ; Sepúlveda-Sánchez, J. M. (Hospital Universitario 12 de Octubre) ; Campayo, M. (Hospital Universitari Mútua Terrassa) ; Chirivella-González, I. (Hospital Clínic Universitari (València)) ; García-del-Muro, X. (Institut d'Investigació Biomèdica de Bellvitge) ; González-del-Alba, A. (Hospital Universitario Son Espases) ; Grande, E. (Hospital Universitario Ramón y Cajal) ; Suárez, Cristina (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. [...]
2017 - 10.1007/s12094-017-1765-4
Clinical & Translational Oncology, Vol. 20 (november 2017) , p. 47-56  
7.
9 p, 1023.2 KB Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain : results of a subgroup analysis of the phase 3 RECOURSE trial / Longo Muñoz, Federico (Hospital Universitario Ramón y Cajal) ; Argilés Martínez, Guillem (Hospital Universitari Vall d'Hebron) ; Taberneroo, J (Hospital Universitari Vall d'Hebron) ; Cervantes, A. (Universitat de València) ; Grávalos, Cristina (Hospital Universitario Doce de Octubre) ; Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Gil Calle, S. (Hospital Carlos Haya) ; Mizuguchi, Hirokazu (Taiho Oncology) ; Carrato, Alfredo (Hospital Universitario Ramón y Cajal) ; Limón, María Luisa (Hospital Universitario Virgen del Rocío) ; García Carbonero, Rocio (Hospital Universitario Doce de Octubre) ; Universitat Autònoma de Barcelona
TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. [...]
2017 - 10.1007/s12094-016-1528-7
Clinical & Translational Oncology, Vol. 19, Issue 2 (February 2017) , p. 227-235  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.